Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular markers in low-grade gliomas: predictive or prognostic?

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jul 2011

Hartmann Christian, Hentschel Bettina, Tatagiba Marcos, Schramm Johannes, Schnell Oliver, Seidel Clemens, Stein Robert, Reifenberger Guido, Pietsch Torsten, von Deimling Andreas, Loeffler Markus, Weller Michael

Abstract excerpt

PURPOSE: To investigate whether TP53 mutation, 1p/19q codeletions, O(6)-methylguanylmethyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation predict natural course of disease or response to radiotherapy or chemotherapy or both in low-grade glioma patients. EXPERIMENTAL DESIGN: Cohort A consisted of 89 patients with diffuse astrocytoma World Health Organization (WHO) grade II...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Progression

Share to DNA Methylation

Share to Glioma

Share to Prognosis

Share to Survival Analysis

Share to Young Adult

Source

Identifiers

PMID: 21558404
DOI: 10.1158/1078-0432.CCR-10-3194

Genes

IDH1
MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular markers in low-grade gliomas: predictive or prognostic?PMID 21558404Read ↗

IDH1 mutation is prognostic for diffuse astrocytoma but not low-grade oligodendrogliomas in patients not treated with early radiotherapy.Semantic proximity Read ↗

Predictive and prognostic factors for gliomas.Semantic proximity Read ↗

The role of clinical and molecular factors in low-grade gliomas: what is their impact on survival?Semantic proximity Read ↗

IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.Semantic proximity Read ↗

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.Semantic proximity Read ↗

Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.Semantic proximity Read ↗

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.Semantic proximity Read ↗

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.Semantic proximity Read ↗

Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.Semantic proximity Read ↗

Molecular classification of low-grade diffuse gliomas.Semantic proximity Read ↗

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.Semantic proximity Read ↗

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.